Newsroom

Press Releases

Saniona Icon blue
August 25, 2022
Three Months Ended June 30, 2022 (2021) Six Months Ended June 30, 2022 (2021) Revenue was SEK 3.0 M (1.9 M) Revenue was SEK 9.6 M (5.3 M) Operating profit/loss was SEK -91.8 M (-103.6 M) Net profit/loss was SEK -88.6 M (-103.9 M) Operating profit/loss was SEK -225.0 M (-197.7 M) Net profit/loss was
August 16, 2022
PRESS RELEASE August 16 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that it ha s progressed its promising Kv7 epilepsy program into the Lead Optimization Phase , which is the last drug discovery phase before potential selection of a clinical candidat
August 5, 2022
PRESS RELEASE August 5 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that 6,45 0, 734 options have forfeited in 20 22, leading to a reduction in potential dilution from 11.89% to 3.0 6 %. As of December 31, 2021, the company had 8,402,181 options
July 15, 2022
PRESS RELEASE 15 July 202 2 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to attend the extraordinary general
May 25, 2022
  Q1 2022 ( Q1 2021 ) Revenue was SEK 6.6 M (3.4 M) Operating loss was SEK -133.2 M (-94.1 M) Net loss was SEK -133.4 M (-83.4 M) Loss per share was SEK -2.14 (-1.34) Diluted loss per share was SEK -2.14 (-1.34) Business highlights in Q1 2022 Saniona initiated the Multiple Ascending Dose (MAD)
Displaying 1 - 10 of 23